Skip to main content
SpringerLink
Log in

Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker

  • Original Article
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Renin–angiotensin system (RAS) inhibitors may be useful in preventing the occurrence of paroxysmal atrial fibrillation (PAF). However, evaluation of such effect is difficult because many PAF episodes are asymptomatic and not all episodes are detected by intermittent electrocardiographic monitoring. A pacemaker has been developed with dedicated functions for AF detection and electrocardiogram storage. Accordingly, we examined the effect of losartan, an angiotensin receptor blocker on PAF occurrence using this new modality. We enrolled 70 consecutive patients who had undergone dual-chamber pacemaker implantation for sick sinus syndrome. Finally, 62 patients participated in the study. Thirty patients were randomized to the losartan group (mean 43 ± 12 mg/day) and 32 patients to the control group. They were followed up for 3 months. The frequency, the maximum duration and the total duration of PAF recorded by the stored electrocardiograms for the last 1 month during the observation period and study period were compared between the two groups. The change in the frequency of PAF from the observation period in the losartan and control groups was similar (−35 ± 25 vs. −67 ± 62 times; NS). However, the change in the maximum duration and the total duration of PAF was significantly shorter in the losartan group than in the control group (−493 ± 158 vs. −10 ± 69 min; p < 0.05, and −4007 ± 2334 vs. 1119 ± 714 min; p < 0.05, respectively). Losartan suppressed the maximum duration and the total duration of PAF in patients with sick sinus syndrome without hemodynamic changes. This is the first study to show the effect of a renin–angiotensin system inhibitor on the secondary prevention of PAF using the dedicated functions of a pacemaker for PAF detection and electrocardiogram storage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kannel WB, Abbott RD, Savage DD, McNamara PM (1982) Epidemiologic features of atrial fibrillation: the Framingham study. N Engl J Med 306:1018–1022

    Article  CAS  PubMed  Google Scholar 

  2. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22:983–988

    Article  CAS  PubMed  Google Scholar 

  3. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G, Ricci R, Favale S, Zolezzi F, Di Belardino N, Molon G, Drago F, Villani GQ, Mazzini E, Vimercati M, Grammatico A (2005) Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 46:1913–1920

    Article  PubMed  Google Scholar 

  4. Nagamoto Y, Inage T, Yoshida T, Takeuchi T, Gondo T, Fukuda Y, Takii E, Murotani K, Imaizumi T (2012) Atrioventricular nodal ablation versus antiarrhythmic drugs afterpermanent pacemaker implantation for bradycardia-tachycardia syndrome. Heart Vessels 27:174–178

    Article  PubMed  Google Scholar 

  5. Suh SY, Kang WC, Oh PC, Choi H, Moon CI, Lee K, Han SH, Ahn T, Choi IS, Shin EK (2013) Efficacy and safety of aspirin, clopidogrel, and warfarin after coronary artery stenting in Korean patients with atrial fibrillation. Heart Vessels 29(5):578–583

    Article  PubMed  Google Scholar 

  6. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN (2005) Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the valsartan heart failure traial (Val-HeFT). Am Heart J 149:548–557

    Article  CAS  PubMed  Google Scholar 

  7. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S (2006) Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbility (CHARM) program. Am Heart J 152:86–92

    Article  PubMed  Google Scholar 

  8. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the losartan intervention for end point reduction in hypertension(LIFE) study. J Am Coll Cardiol 45:712–719

    Article  CAS  PubMed  Google Scholar 

  9. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A (2003) Enalapril decreases the incidence of atrial Fibrillation in patients with left ventricular dysfunction insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 107:2926–2931

    Article  PubMed  Google Scholar 

  10. Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, Dai Y, Su L, Ling Z, She Q, Luo K, Woo K, Dong J (2006) Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 27:1841–1846

    Article  CAS  PubMed  Google Scholar 

  11. Madrid AH, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C (2002) Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106:331–336

    Article  CAS  PubMed  Google Scholar 

  12. Investigators GISSI-AF, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606–1617

    Article  Google Scholar 

  13. Active I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ (2011) Irbesartan in patients with atrial fibrillation. N Engl J Med 364:928–938

    Article  Google Scholar 

  14. Goette A, Schön N, Kirchhof P, Breithardt G, Fetsch T, Häusler KG, Klein HU, Steinbeck G, Wegscheider K, Meinertz T (2012) Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 5:43–51

    Article  PubMed  Google Scholar 

  15. Sutton R, Stack Z, Heaven D, Ingram A (1999) Mode switching for atrial tachyarrhythmias. Am J Cardiol 83:202D–210D

    Article  CAS  PubMed  Google Scholar 

  16. Naritomi H, Fujita T, Ito S, Ogihara T, Shimada K, Shimamoto K, Tanaka H, Yoshiike N (2008) Efficacy and safety of long-term losartan therapy demonstrated by a prospective observational study in Japanese patients with hypertension: the Japan hypertension evaluation with angiotensin II antagonist losartan therapy (J-HEALTH) study. Hypertens Res 31:295–304

    Article  CAS  PubMed  Google Scholar 

  17. Verheule S, Wilson E, Everett T 4th, Shanbhag S, Golden C, Olgin J (2003) Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. Circulation 107:2615–2622

    PubMed  PubMed Central  Google Scholar 

  18. Verheule S, Sato T, Everett T 4th, Engle SK, Otten D, Rubart-von der Lohe M, Nakajima HO, Nakajima H, Field LJ, Olgin JE (2004) Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-β1. Circ Res 94:1458–1465

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Singh JP, Kulil A, Levin R, Ellinor PT, Ruskin J, Choudhry NK (2012) Renin–angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Europace 14:1287–1293

    Article  PubMed  Google Scholar 

  20. Nakashima H, Kumagai K (2007) Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 71:1977–1982

    Article  CAS  PubMed  Google Scholar 

  21. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010) Prevention of atrial fibrillation by renin–angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55:2299–2307

    Article  PubMed  Google Scholar 

  22. Israel CW, Grönefeld G, Ehrlich JR, Li YG, Hohnloser SH (2004) Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device. J Am Coll Cardiol 43:47–52

    Article  PubMed  Google Scholar 

  23. Quirino G, Giammaria M, Corbucci G, Pistelli P, Turri E, Mazza A, Perucca A, Checchinato C, Dalmasso M, Barold SS (2009) Diagnosis of paroxysmal atrial fibrillation in patients with implanted pacemakers: relationship to symptoms and other variables. PACE 32:91–98

    Article  PubMed  Google Scholar 

  24. Hirayama Y, Atarashi H, Kobayashi Y, Horie T, Iwasaki Y, Maruyama M, Miyauchi Y, Ohara T, Yashima M, Takano T (2005) Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. Circ J 69:671–676

    Article  CAS  PubMed  Google Scholar 

  25. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45:1832–1839

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Cardio-Vascular Medicine, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan

    Eiichi Takii, Tomohito Inage, Teruhisa Yoshida, Masatsugu Ohe, Takeki Gondo, Go Haraguchi, Shogo Ito, Jun Kumanomido, Tsutomu Imaizumi & Yoshihiro Fukuomoto

Authors
  1. Eiichi Takii
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomohito Inage
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teruhisa Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masatsugu Ohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeki Gondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Go Haraguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shogo Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Kumanomido
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tsutomu Imaizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoshihiro Fukuomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomohito Inage.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takii, E., Inage, T., Yoshida, T. et al. Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker. Heart Vessels 31, 402–407 (2016). https://doi.org/10.1007/s00380-015-0627-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-015-0627-7

Keywords

Search

Navigation